Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Jun
18
Today In Oncology
Overall Survival With EBRT in Hepatocellular Carcinoma
HCC TACE Plus STRIDE With or Without Lenvatinib
St Jude Redesignation Marks Collaboration With WHO Toward Improved Pediatric Cancer Outcomes Globally
FDA Warns of Ongoing Breast Biopsy Needle Shortage
New ACSM Expert Consensus Statement: Exercise in Children and Adolescents With Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo